CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
-
Luis Suarez apologizes after Leagues Cup spitting incident
-
Trump signs order to lower US tariffs on Japan autos to 15%
-
Germany lose opening World Cup qualifier as Spain cruise
-
Nagelsmann slams 'lack of emotion' in Germany's loss to Slovakia
-
Germany fall 2-0 to Slovakia in World Cup qualifying opener
-
Cape Verde islanders win to stay on course for World Cup debut
-
Breetzke stars as South Africa edge England by five runs for ODI series win
-
Germany fall 2-0 to Slovakia in 2026 World Cup qualifying opener
-
Flamengo's Henrique out for 12 games for alleged match-fixing
-
Cash on hand to clinch point for Poland against Netherlands
-
Spain thrash Bulgaria in opening 2026 World Cup qualifier
-
Argentine Congress overturns Milei veto on disability funds
-
Japanese star Oda chasing career Slam at US Open
-
Djokovic aims to 'mess up' Sinner-Alcaraz plans at US Open
-
Trump's Fed pick plans to keep White House job while at central bank
-
In face of US 'threat,' how does Venezuela's military stack up?
-
Israel military says controls 40 percent of Gaza City
-
Tennis icon Borg battling cancer says publicity for autobiography
-
Argentina charges Nazi's daughter for concealing decades-old art theft
-
Portugal releases first details of 16 killed in funicular crash
-
US sues power company over deadly Los Angeles wildfire
-
After change of club and Italy coach, fresh beginnings for Donnarumma
-
Levy makes shock decision to quit as Spurs chairman
-
UK court convicts asylum seeker of sexual assault
-
Fashion, cinema stars hail 'love affair' with Armani
-
France star Mbappe calls for players to get more time off
-
Trump's Fed governor pick vows to uphold central bank independence
-
Norris brushes off Dutch setback before Italian GP battle with Piastri
-
In-form Breetzke stars as South Africa post 330-8 against England
-
France says 26 countries commit to Ukraine deployment if peace agreed
-
White House quietly drops WTO, ILO from foreign aid cut list
-
Wales edge Kazakhstan to boost World Cup hopes
-
Ayuso sprints to Vuelta stage 12 victory as tensions ease
-
Could humans become immortal, as Putin was heard telling Xi?
-
Stock markets advance with eyes on US jobs data
-
Xi tells Kim North Korea's importance to China 'will not change'
-
France detains seven over new cryptocurrency kidnapping
-
Europe pledges postwar 'reassurance force' for Ukraine: Macron
-
Hollywood hails Armani, designer to the stars
-
RFK Jr defends health agency shake up, Democrats call for his ouster
-
Bike-loving Dutch weigh ban on fat bikes from cycle lanes
-
With restraint, Armani stitched billion-dollar fashion empire
-
France, Switzerland agree on Rhone, Lake Geneva water management
-
US trade gap widest in 4 months as imports surged ahead of tariffs
-
Portugal mourns 16 killed in Lisbon funicular crash
-
Alarm in Germany as 'dangerous' Maddie suspect set to walk
-
Italian fashion icon Giorgio Armani dead at 91
-
Pro-Palestinian protests rock Spain's Vuelta cycling race
-
Tourists and locals united in grief after Lisbon funicular crash
-
Comedy writer at centre of UK free-speech row in court on harassment charge
NYSE - LSE
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
C.Garcia--AMWN